Protein structures in virtual screening: A case study with CDK2

被引:43
作者
Thomas, MP [1 ]
McInnes, C [1 ]
Fischer, PM [1 ]
机构
[1] Cyclacel Ltd, Dundee DD1 5JJ, Scotland
关键词
D O I
10.1021/jm050554i
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The influence of protein structure on the successful reproduction of known ligand poses by high-throughput docking programs is rarely discussed. Two commonly used programs, Glide and GOLD, were used to dock a set of CDK2 inhibitors of known bound pose into 20 different CDK2 structures. The numbers of docked poses that reproduced the known pose are reported. Depending on the program and protein structure, 0.3%-96.2% of the ligands docked with the correct pose. Although it is not possible to say that any one structure is "the best" for virtual screening, there are some structures that are clearly better than others. The main determinants of this are the volume of the binding site into which the ligands are docked and the exact orientation of the residues forming, the binding site.
引用
收藏
页码:92 / 104
页数:13
相关论文
共 57 条
[1]   High-throughput docking as a source of novel drug leads [J].
Alvarez, JC .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (04) :365-370
[2]   Imidazo[1,2-a]pyridines:: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation [J].
Anderson, M ;
Beattie, JF ;
Breault, GA ;
Breed, J ;
Byth, KF ;
Culshaw, JD ;
Ellston, RPA ;
Green, S ;
Minshull, CA ;
Norman, RA ;
Pauptit, RA ;
Stanway, J ;
Thomas, AP ;
Jewsbury, PJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :3021-3026
[3]   Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].
Arris, CE ;
Boyle, FT ;
Calvert, AH ;
Curtin, NJ ;
Endicott, JA ;
Garman, EF ;
Gibson, AE ;
Golding, BT ;
Grant, S ;
Griffin, RJ ;
Jewsbury, P ;
Johnson, LN ;
Lawrie, AM ;
Newell, DR ;
Noble, MEM ;
Sausville, EA ;
Schultz, R ;
Yu, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2797-2804
[4]   Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 1: Identification and optimisation of substituted 4,6-bis anilino pyrimidines [J].
Beattie, JF ;
Breault, GA ;
Ellston, RPA ;
Green, S ;
Jewsbury, PJ ;
Midgley, CJ ;
Naven, RT ;
Minshull, CA ;
Pauptit, RA ;
Tucker, JA ;
Pease, JE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (18) :2955-2960
[5]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[6]   Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase [J].
Birch, L ;
Murray, CW ;
Hartshorn, MJ ;
Tickle, IJ ;
Verdonk, ML .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (12) :855-869
[7]   Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations [J].
Bissantz, C ;
Folkers, G ;
Rognan, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (25) :4759-4767
[8]   Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): Design, synthesis, enzymatic activities, and X-ray crystallographic analysis [J].
Bramson, HN ;
Corona, J ;
Davis, ST ;
Dickerson, SH ;
Edelstein, M ;
Frye, SV ;
Gampe, RT ;
Harris, PA ;
Hassell, A ;
Holmes, WD ;
Hunter, RN ;
Lackey, KE ;
Lovejoy, B ;
Luzzio, MJ ;
Montana, V ;
Rocque, WJ ;
Rusnak, D ;
Shewchuk, L ;
Veal, JM ;
Walker, DH ;
Kuyper, LF .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (25) :4339-4358
[9]   Molecular recognition and docking algorithms [J].
Brooijmans, N ;
Kuntz, ID .
ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 2003, 32 :335-373
[10]   Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity [J].
Brown, NR ;
Noble, MEM ;
Lawrie, AM ;
Morris, MC ;
Tunnah, P ;
Divita, G ;
Johnson, LN ;
Endicott, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (13) :8746-8756